ERIN BARTH: Open Payments
NPI 1265951578 · SOUTH BEND, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,207 in 160 payments from 26 companies in 2025. Trend: 2023 $1,813 · 2024 $1,752 · 2025 $3,207
Food & beverage: $3,107Education: $100
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 14 | $474 |
| GlaxoSmithKline, LLC. | 25 | $354 |
| Verona Pharma, Inc. | 30 | $270 |
| Regeneron Healthcare Solutions, Inc. | 6 | $221 |
| Viatris Specialty LLC | 15 | $208 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $172 |
| Actelion Pharmaceuticals US, Inc. | 4 | $146 |
| GENZYME CORPORATION | 7 | $144 |
| Madrigal Pharmaceuticals | 1 | $140 |
| Genentech USA, Inc. | 5 | $129 |
Products named: DUPIXENT, Ohtuvayre, AIRSUPRA, YUPELRI, TEZSPIRE, TRELEGY ELLIPTA, NUCALA, REZDIFFRA.
Industry payments across IN — which companies pay providers there.
